Id: acc1513
Group: 2sens
Protein: FKHR
Gene Symbol: FOXO1
Protein Id: Q12778
Protein Name: FOXO1_HUMAN
PTM: phosphorylation
Site: Ser256
Site Sequence: GKSPRRRAASMDNNSKFAKSR
Disease Category: Cancer
Disease: Lung Cancer
Disease Subtype: LUAD
Disease Cellline: GLC-82
Disease Info:
Drug: SYUNZ-16
Drug Info: -
Effect: modulate
Effect Info: SYUNZ-16 induces apoptosis in human lung adenocarcinoma cells GLC-82 and hepatoma cells Hep3B and inhibits tumor growth by suppressing the activity of PKB/AKT kinase (protein phosphorylation) and blocking the AKT/FOXO signaling pathway.
Note:
Score: 4.0
Pubmed(PMID): 19904742
Sentence Index:
Sentence:

Sequence & Structure:

MAEAPQVVEIDPDFEPLPRPRSCTWPLPRPEFSQSNSATSSPAPSGSAAANPDAAAGLPSASAAAVSADFMSNLSLLEESEDFPQAPGSVAAAVAAAAAAAATGGLCGDFQGPEAGCLHPAPPQPPPPGPLSQHPPVPPAAAGPLAGQPRKSSSSRRNAWGNLSYADLITKAIESSAEKRLTLSQIYEWMVKSVPYFKDKGDSNSSAGWKNSIRHNLSLHSKFIRVQNEGTGKSSWWMLNPEGGKSGKSPRRRAASMDNNSKFAKSRSRAAKKKASLQSGQEGAGDSPGSQFSKWPASPGSHSNDDFDNWSTFRPRTSSNASTISGRLSPIMTEQDDLGEGDVHSMVYPPSAAKMASTLPSLSEISNPENMENLLDNLNLLSSPTSLTVSTQSSPGTMMQQTPCYSFAPPNTSLNSPSPNYQKYTYGQSSMSPLPQMPIQTLQDNKSSYGGMSQYNCAPGLLKELLTSDSPPHNDIMTPVDPGVAQPNSRVLGQNVMMGPNSVMSTYGSQASHNKMMNPSSHTHPGHAQQTSAVNGRPLPHTVSTMPHTSGMNRLTQVKTPVQVPLPHPMQMSALGGYSSVSSCNGYGRMGLLHQEKLPSDLDGMFIERLDCDMESIIRNDLMDGDTLDFNFDNVLPNQSFPHSVKTTTHSWVSG

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
FOXO1-Ser256
Cancer Intensity
BRCA -0.041
COAD
HGSC 1.442
ccRCC
GBM -0.737
HNSC 0.067
LUAD -0.248
LUSC -0.693
non_ccRCC 1.745
PDAC -0.217
UCEC -1.318

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
S 256 D Hepatitis Phosphorylation 18316359
S 256 U Astrocytoma/astrocytoma glioblastoma Phosphorylation 23874926
S 256 U Breast cancer Phosphorylation 36797347

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM
Protein Gene PTM Position Modified sequence Cell Drug pEC50 Regulation Experiment
Q12778 FOXO1 P Ser256 AAS(ph)MDNNSK A431 Afatinib 7.7885 down
Q12778 FOXO1 P Ser256 RAAS(ph)MDNNSK A431 Afatinib 7.9121 down
Q12778 FOXO1 P Ser256 AAS(ph)MDNNSK A431 Afatinib 7.6536 down
Q12778 FOXO1 P Ser256 AAS(ph)MDNNSK A431 Dasatinib 5.0118 down
Q12778 FOXO1 P Ser256 AAS(ph)MDNNSK A431 Gefitinib 5.8291 down
Q12778 FOXO1 P Ser256 AAS(ph)MDNNSK ARH-77 Rituximab -4.2161 -
Q12778 FOXO1 P Ser256 AAS(ph)MDNNSK SU-DHL-4 Rituximab -3.1969 -
Q12778 FOXO1 P Ser256 AAS(ph)MDNNSK ARH-77 Rituximab -1.2622 -
Q12778 FOXO1 P Ser256 AAS(ph)MDNNSK Ramos Rituximab -2.9325 -
Q12778 FOXO1 P Ser256 RAAS(ph)MDNNSK Ramos Rituximab -2.9551 -
Q12778 FOXO1 P Ser256 RAAS(ph)MDNNSK Ramos Rituximab -2.6044 -
Q12778 FOXO1 P Ser256 AAS(ph)MDNNSK Ramos Rituximab -2.7534 -
Q12778 FOXO1 P Ser256 AAS(ph)MDNNSK Ramos Rituximab -2.7385 -
Q12778 FOXO1 P Ser256 AAS(ph)MDNNSK Ramos Rituximab -2.7296 -
Q12778 FOXO1 P Ser256 RAAS(ph)MDNNSK Ramos Rituximab -2.732 -
Q12778 FOXO1 P Ser256 AAS(ph)MDNNSK Ramos Rituximab -5.4119 -
Q12778 FOXO1 P Ser256 AAS(ph)MDNNSK Ramos Rituximab -1.6991 -
Q12778 FOXO1 P Ser256 AAS(ph)MDNNSK SU-DHL-4 Rituximab 2.6004 -
Q12778 FOXO1 P Ser256 RAAS(ph)MDNNSK SU-DHL-4 Rituximab -1.7272 -
Q12778 FOXO1 P Ser256 AAS(ph)MDNNSK SU-DHL-4 Rituximab 0.5426 -
Q12778 FOXO1 P Ser256 AAS(ph)MDNNSK SU-DHL-4 Rituximab -1.4717 -
Q12778 FOXO1 P Ser256 RAAS(ph)MDNNSK SU-DHL-4 Rituximab -2.9988 -
Q12778 FOXO1 P Ser256 AAS(ph)MDNNSK SU-DHL-4 Rituximab -0.4361 -
Q12778 FOXO1 P Ser256 AAS(ph)MDNNSK SU-DHL-4 Rituximab 1.8741 -
Q12778 FOXO1 P Ser256 AAS(ph)MDNNSK A431 Gefitinib 6.6281 -
Q12778 FOXO1 P Ser256 RAAS(ph)MDNNSK A431 Afatinib 7.8735 -
Q12778 FOXO1 P Ser256 AAS(ph)MDNNSK A431 Afatinib 7.7449 -
Q12778 FOXO1 P Ser256 RAAS(ph)MDNNSK A431 Afatinib 7.905 -
Q12778 FOXO1 P Ser256 AAS(ph)MDNNSK A431 Afatinib 7.7638 -
Q12778 FOXO1 P Ser256 AAS(ph)MDNNSK A431 Dasatinib 6.708 -
Q12778 FOXO1 P Ser256 RAAS(ph)MDNNSK A431 Dasatinib 5.7366 -
Q12778 FOXO1 P Ser256 AAS(ph)MDNNSK A431 Dasatinib 6.9326 -
Q12778 FOXO1 P Ser256 RAAS(ph)MDNNSK A431 Dasatinib 5.8864 -
Q12778 FOXO1 P Ser256 AAS(ph)MDNNSK A431 Dasatinib 4.5562 -
Q12778 FOXO1 P Ser256 AAS(ph)MDNNSK ARH-77 Rituximab -2.9319 -
Q12778 FOXO1 P Ser256 RAAS(ph)MDNNSK A431 Gefitinib 4.7784 -
Q12778 FOXO1 P Ser256 AAS(ph)MDNNSK A431 Gefitinib 6.3613 -
Q12778 FOXO1 P Ser256 AAS(ph)MDNNSK A431 Gefitinib 7.2908 -
Q12778 FOXO1 P Ser256 RAAS(ph)MDNNSK A431 Gefitinib 6.6456 -
Q12778 FOXO1 P Ser256 AAS(ph)MDNNSK ARH-77 Rituximab -4.0778 -
Q12778 FOXO1 P Ser256 AAS(ph)MDNNSK ARH-77 Rituximab -2.4534 -
Q12778 FOXO1 P Ser256 AAS(ph)MDNNSK ARH-77 Rituximab -4.2442 -
Q12778 FOXO1 P Ser256 AAS(ph)MDNNSK ARH-77 Rituximab -1.2596 -

pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.

Function score:

source: funscoR

No data.

Cross Links: